
Prostate Cancer
Latest News

Latest Videos

CME Content
More News

The FDA has approved a non-alcohol formulation of docetaxel as a treatment for patients with breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer.

Philip W. Kantoff, MD, who has made many contributions in prostate cancer research at the laboratory and leadership levels, was honored in the Genitourinary Cancer category with a 2014 Giants of Cancer Care® award, a program that the Intellisphere® Oncology Specialty Group launched to honor leaders in the field.

Jay Ciezki, MD, Department of Radiation Oncology, Cleveland Clinic, discusses an analysis of patients with various malignancies who commonly presented with advanced disease.

Emmanuel Antonarakis, MBBCh, associate professor of Oncology, associate professor of Urology at Johns Hopkins Medicine, discusses the use of galeterone in prostate cancer.

Philip J. Buffington, MD, discussed new screening methods and hormonal therapies being utilized for patients with metastatic prostate cancer.

Joe O'Sullivan, MD, clinical professor, School of Medicine, Dentistry and Biomedical Sciences, Centre for Cancer Research and Cell Biology, at Queen’s University Belfast, discusses toxicities associated with radium-223 dichloride for patients with metastatic castration-resistant prostate cancer.

Gary Kirsh, MD, president of The Urology Group and LUGPA, Kirsh provides insight on treating prostate cancer within the context of urology, as well as the benefits of a multidisciplinary approach.

Raoul S. Concepcion, MD, FACS, discussed novel therapies for treating mCRPC and deciding which patients are appropriate candidates.

Amid an expansion of therapeutic options for men with advanced prostate cancer, evidence is building that introducing recently developed agents and regimens earlier in the treatment timeline can benefit patients in several disease settings.

When compared with the National Comprehensive Cancer Network (NCCN) breast cancer guidelines, the corresponding prostate cancer guidelines fall short in one distinct characteristic—the lack of a molecular test in tissue-based platforms at this point in time.

Clinical trials are now assessing how to best use radium-223 (Xofigo) in combination with androgen inhibitors, following the rapid approval of several agents for men with castration-resistant prostate cancer.

Recent trends suggest a shift away from radiation therapy and more toward radical prostatectomy for patients with high-risk prostate cancer.





































































